All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We asked, When is CAR-T a good option for patients with follicular and marginal zone lymphomas?
When is CAR-T a good option for patients with follicular and marginal zone lymphomas?
Salles begins by discussing studies in this area, such as ZUMA-5 and ELARA, highlighting high response and remission rates. However, Salles notes that we need more data on durability and the results of bi-specific antibodies compared with CAR-T. Salles concludes by predicting a promising future for therapies in indolent B-cell malignancies.
Which patients with aggressive B-cell NHL do not qualify for CAR-T?
During the 4th European CAR T-cell Meeting the Lymphoma Hub was pleased to speak with, Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain, ES. We asked, Which patients with...
ASH 2019 | Practice-changing abstracts in lymphoma and CLL
The Lymphoma Hub has developed a downloadable resource, which provides an update on the practice-changing abstracts in lymphoma and CLL from ASH 2019 in preparation for ASH 2020.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox